LSTA
Price:
$3.1
Market Cap:
$25.79M
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerl...[Read more]
Industry
Biotechnology
IPO Date
1999-03-01
Stock Exchange
NASDAQ
Ticker
LSTA
According to Lisata Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -46.22%. This represents a change of 294.83% compared to the average of -11.71% of the last 4 quarters.
The mean historical ROE of Lisata Therapeutics, Inc. over the last ten years is -137.70%. The current -46.22% ROE has changed -66.43% with respect to the historical average. Over the past ten years (40 quarters), LSTA's ROE was at its highest in in the March 2017 quarter at 1.18%. The ROE was at its lowest in in the December 2015 quarter at -139.99%.
Average
-137.70%
Median
-62.36%
Minimum
-668.65%
Maximum
45.50%
Discovering the peaks and valleys of Lisata Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 263.73%
Maximum Annual ROE = 45.50%
Minimum Annual Increase = -194.19%
Minimum Annual ROE = -668.65%
Year | ROE | Change |
---|---|---|
2023 | -43.28% | -46.86% |
2022 | -81.45% | 173.56% |
2021 | -29.77% | 18.84% |
2020 | -25.05% | -74.06% |
2019 | -96.57% | 125.34% |
2018 | -42.85% | -194.19% |
2017 | 45.50% | -106.80% |
2016 | -668.65% | 96.03% |
2015 | -341.10% | 263.73% |
2014 | -93.78% | 50.46% |
The current ROE of Lisata Therapeutics, Inc. (LSTA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-51.50%
5-year avg
-55.22%
10-year avg
-137.70%
Lisata Therapeutics, Inc.’s ROE is greater than Lixte Biotechnology Holdings, Inc. (-112.90%), greater than Histogen Inc. (-108.33%), greater than Imunon, Inc. (-165.51%), less than Kineta, Inc. (934.78%), greater than Rezolute, Inc. (-60.90%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than XOMA Corporation (-19.34%), greater than Protagenic Therapeutics, Inc. (-238.37%), greater than Tempest Therapeutics, Inc. (-201.10%), greater than Pulmatrix, Inc. (-61.78%), greater than Onconova Therapeutics, Inc. (-144.95%), less than Catalyst Biosciences, Inc. (1.20%), greater than Bio-Path Holdings, Inc. (-2842.40%), greater than Moleculin Biotech, Inc. (-100.16%), greater than Alpine Immune Sciences, Inc. (-14.86%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Ampio Pharmaceuticals, Inc. (-143.77%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Candel Therapeutics, Inc. (-629.29%),
Company | ROE | Market cap |
---|---|---|
-112.90% | $4.39M | |
-108.33% | $939.79K | |
-165.51% | $14.98M | |
934.78% | $8.08M | |
-60.90% | $240.80M | |
-23.13% | $108.71M | |
-19.34% | $332.97M | |
-238.37% | $3.37M | |
-201.10% | $31.26M | |
-61.78% | $7.30M | |
-144.95% | $20.90M | |
1.20% | $19.42M | |
-2842.40% | $2.51M | |
-100.16% | $6.83M | |
-14.86% | $4.46B | |
-54.72% | $30.44M | |
-143.77% | $2.50K | |
-70.40% | $349.21M | |
-629.29% | $197.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lisata Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lisata Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Lisata Therapeutics, Inc.'s ROE?
How is the ROE calculated for Lisata Therapeutics, Inc. (LSTA)?
What is the highest ROE for Lisata Therapeutics, Inc. (LSTA)?
What is the 3-year average ROE for Lisata Therapeutics, Inc. (LSTA)?
What is the 5-year average ROE for Lisata Therapeutics, Inc. (LSTA)?
How does the current ROE for Lisata Therapeutics, Inc. (LSTA) compare to its historical average?